THU0427 Sustained Improvements in Skin Outcomes Following Certolizumab Pegol Treatment of Psoriatic Arthritis Patients with Prior Anti-TNF Exposure or Severe Skin Involvement at Baseline

Abstract

BackgroundPrevious reports of RAPID-PsA (NCT01087788) have demonstrated the efficacy of certolizumab pegol (CZP) in patients (pts) with psoriatic arthritis (PsA) to Week (Wk) 96 of treatment.1ObjectivesHere we report the efficacy...